HCA Healthcare (HCA) to Release Earnings on Friday

Key Points

• HCA Healthcare is set to release its Q3 2025 results on October 24th, with expectations of earnings of $5.64 per share and revenue of $18.5474 billion.
• The company recently reported a 6.4% year-over-year revenue increase and exceeded earnings expectations in its last quarterly results with $6.84 per share.
• Analyst ratings for HCA Healthcare vary, with target prices ranging from $370.00 to $465.00, showing a consensus average target price of $431.07.

HCA Healthcare (NYSE:HCA - Get Free Report) is projected to issue its Q3 2025 results before the market opens on Friday, October 24th. Analysts expect the company to announce earnings of $5.64 per share and revenue of $18.5474 billion for the quarter. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS.Individuals can check the company's upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Friday, October 24, 2025 at 10:00 AM ET.

HCA Healthcare (NYSE:HCA - Get Free Report) last posted its quarterly earnings results on Friday, July 25th. The company reported $6.84 earnings per share for the quarter, beating the consensus estimate of $6.20 by $0.64. The firm had revenue of $18.61 billion during the quarter, compared to the consensus estimate of $18.49 billion. HCA Healthcare had a net margin of 8.21% and a negative return on equity of 7,363.11%. The company's revenue was up 6.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.50 earnings per share. On average, analysts expect HCA Healthcare to post $25 EPS for the current fiscal year and $28 EPS for the next fiscal year.

HCA Healthcare Stock Down 0.2%

Shares of NYSE HCA opened at $419.53 on Friday. The business has a fifty day simple moving average of $409.17 and a two-hundred day simple moving average of $377.66. The firm has a market cap of $98.17 billion, a PE ratio of 17.63, a price-to-earnings-growth ratio of 1.33 and a beta of 1.40. HCA Healthcare has a twelve month low of $289.98 and a twelve month high of $439.01.

HCA Healthcare Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Tuesday, September 16th were paid a dividend of $0.72 per share. The ex-dividend date was Tuesday, September 16th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.7%. HCA Healthcare's dividend payout ratio (DPR) is currently 12.11%.

Insiders Place Their Bets

In other news, EVP Michael S. Cuffe sold 3,836 shares of the stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $418.84, for a total value of $1,606,670.24. Following the transaction, the executive vice president directly owned 31,503 shares of the company's stock, valued at approximately $13,194,716.52. This represents a 10.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.30% of the company's stock.

Institutional Trading of HCA Healthcare

Several large investors have recently made changes to their positions in the business. B. Riley Wealth Advisors Inc. purchased a new position in shares of HCA Healthcare during the second quarter worth $383,000. Hudson Bay Capital Management LP raised its position in HCA Healthcare by 27.2% during the second quarter. Hudson Bay Capital Management LP now owns 1,844 shares of the company's stock valued at $706,000 after acquiring an additional 394 shares in the last quarter. Geneos Wealth Management Inc. boosted its position in HCA Healthcare by 13.9% in the 2nd quarter. Geneos Wealth Management Inc. now owns 3,997 shares of the company's stock worth $1,531,000 after purchasing an additional 487 shares in the last quarter. Evergreen Capital Management LLC lifted its stake in shares of HCA Healthcare by 15.3% in the 2nd quarter. Evergreen Capital Management LLC now owns 1,284 shares of the company's stock valued at $492,000 after purchasing an additional 170 shares during the period. Finally, MUFG Securities EMEA plc acquired a new position in shares of HCA Healthcare in the second quarter worth about $196,000. 62.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HCA has been the subject of a number of analyst reports. KeyCorp upped their target price on HCA Healthcare from $370.00 to $465.00 and gave the stock an "overweight" rating in a report on Wednesday, October 8th. Wolfe Research lowered HCA Healthcare from an "outperform" rating to a "peer perform" rating in a research note on Monday, July 28th. Robert W. Baird raised their price target on shares of HCA Healthcare from $380.00 to $423.00 and gave the company a "neutral" rating in a report on Thursday, August 14th. Wells Fargo & Company increased their target price on shares of HCA Healthcare from $375.00 to $412.00 and gave the company an "equal weight" rating in a research report on Tuesday, October 7th. Finally, Truist Financial set a $460.00 price objective on HCA Healthcare in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat.com, HCA Healthcare has an average rating of "Moderate Buy" and an average target price of $431.07.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.